Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-positive, HER2-negative Breast Neoplasms”

338 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 338 results

Not applicableLooking for participantsNCT05890287
What this trial is testing

Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Who this might be right for
HR Positive HER2 Negative Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06635447
What this trial is testing

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Who this might be right for
Breast Cancer
AstraZeneca 293
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07367178
What this trial is testing

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerAdvanced HR+/HER2- Breast CancerAdvanced Triple-Negative Breast Cancer
MedSIR 30
Large-scale testing (Phase 3)Ended earlyNCT03326674
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 685
Not applicableStudy completedNCT05132101
What this trial is testing

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Who this might be right for
Metastatic Breast Cancer
Pfizer 2,758
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07767474
What this trial is testing

Evaluate ATX-898 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Antares Therapeutics, Inc 343
Large-scale testing (Phase 3)Study completedNCT02028507
What this trial is testing

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 693
Testing effectiveness (Phase 2)Looking for participantsNCT07288359
What this trial is testing

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 205
Early research (Phase 1)Study completedNCT04481113
What this trial is testing

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+17 more
OHSU Knight Cancer Institute 8
Large-scale testing (Phase 3)Study completedNCT02511639
What this trial is testing

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer Metastatic
Istituto Oncologico Veneto IRCCS 110
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Early research (Phase 1)WithdrawnNCT05905341
What this trial is testing

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Who this might be right for
Breast CancerOvarian CancerLiposarcoma+3 more
Pfizer
Testing effectiveness (Phase 2)WithdrawnNCT01288092
What this trial is testing

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT04460430
What this trial is testing

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 12
Large-scale testing (Phase 3)Looking for participantsNCT05860465
What this trial is testing

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 254
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Large-scale testing (Phase 3)Looking for participantsNCT07071337
What this trial is testing

SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Large-scale testing (Phase 3)Looking for participantsNCT06977893
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 194
Next Page